🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers.

An International Challenge

Gonorrhoea infections are increasing globally, with estimates suggesting more than 82 million instances each year. Notably increased rates are reported in the African continent and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the face of rising global incidence, the spread of superbugs and the very limited treatment choices at this time.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per results detailed in a major medical journal, the new drug cured more than 90% of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves two antibiotics. The trial involved hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in many developing nations.

Clinicians directly involved have shared positive views. Access to a one-pill regimen such as this is described as a "critical tool" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.